Thromb Haemost 2018; 118(02): 279-287
DOI: 10.1160/TH17-06-0416
Coagulation and Fibrinolysis
Schattauer GmbH Stuttgart

Relation of Renal Dysfunction to Quality of Anticoagulation Control in Patients with Atrial Fibrillation: The FANTASIIA Registry

María Asunción Esteve-Pastor
,
José Miguel Rivera-Caravaca
,
Inmaculada Roldán-Rabadán
,
Vanessa Roldán
,
Javier Muñiz
,
Paula Raña-Míguez
,
Martín Ruiz-Ortiz
,
Ángel Cequier
,
Vicente Bertomeu-Martínez
,
Lina Badimón
,
Manuel Anguita
,
Gregory Y. H. Lip*
,
Francisco Marín*
,
on behalf of FANTASIIA Study Investigators
Funding The FANTASIIA registry was funded by an unconditional grant from Pfizer/Bristol-Myers-Squibb and by grants from the Instituto de Salud Carlos III (Madrid)-FEDER (RD12/0042/0068, RD12/0042/0010, RD12/0042/0069 and RD12/0042/0063).
The authors are supported by RD12/0042/0049 (RETICS) from ISCIII and PI13/00513/FEDER from ISCIII. Fundación Séneca (19245/PI/14), Instituto Murciano de Investigación Biosanitaria (IMIB16/AP/01/06). José Miguel Rivera-Caravaca has received a grant from Sociedad Española de Trombosis y Hemostasia (SETH; grant for short international training stays 2016).
Further Information

Publication History

16 June 2017

02 November 2017

Publication Date:
29 January 2018 (online)

Abstract

Background One-third of atrial fibrillation (AF) patients have chronic kidney disease (CKD), a condition that itself increases thromboembolic and major bleeding risks, especially in patients with severe CKD. Bleeding would be accentuated by suboptimal anticoagulation control with vitamin K antagonists (VKA).

Purpose This article aimed to investigate the incidence of cardiovascular events, mortality and quality of anticoagulation in relation to CKD in a ‘real-world’ prospective cohort of AF patients included in the FANTASIIA registry.

Methods We analysed consecutive AF patients who were prospectively recruited with a year of follow-up. The quality of anticoagulation was estimated by time in therapeutic range (TTR). The annual incidence of events was analysed.

Results We studied 1,936 patients (male: 55.7%, mean: 73.8 ± 9.4 years): 445 (22.9%) had normal function, 698 (36.1%) had mild CKD, 713 (36.8%) had moderate CKD and 80 (4.2%) had severe CKD. Patients with estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m2 (severe CKD) had lower TTR (53.3 ± 25.6% vs. 61.8 ± 25.1%, p = 0.007) and higher proportion of poor TTR (67.2 vs. 51.8%; p = 0.014) than patients with eGFR ≥30 mL/min/1.73 m2. Severe CKD was significantly associated with cardiovascular mortality (hazard ratio [HR]: 9.33; p = 0.002), major bleeding (HR: 2.94; p = 0.036) and major adverse cardiovascular events (MACE) (HR: 4.93; p = 0.004). Importantly, 375 patients (21.1%) showed a deteriorating eGFR of ≥10 mL/min during the follow-up, with significantly higher mortality and cardiovascular events.

Conclusion In a prospective and real-world AF registry, approximately 67% of patients with severe CKD had poor anticoagulation control while taking VKA. The presence of severe CKD was an independent factor for cardiovascular mortality, MACE and major bleeding. Worsening eGFR of only ≥10 mL/min during follow-up was significantly associated with mortality and major bleeding.

* Joint senior authors.


Supplementary Material

 
  • References

  • 1 Potpara TS, Lenarczyk R, Larsen TB, Deharo JC, Chen J, Dagres N. ; Conducted by the Scientific Initiatives Committee, European Heart Rhythm Association. Management of atrial fibrillation in patients with chronic kidney disease in Europe Results of the European Heart Rhythm Association Survey. Europace 2015; 17 (12) 1862-1867
  • 2 Jun M, James MT, Manns BJ. , et al; Alberta Kidney Disease Network. The association between kidney function and major bleeding in older adults with atrial fibrillation starting warfarin treatment: population based observational study. BMJ 2015; 350: h246
  • 3 Soliman EZ, Prineas RJ, Go AS. , et al; Chronic Renal Insufficiency Cohort (CRIC) Study Group. Chronic kidney disease and prevalent atrial fibrillation: the Chronic Renal Insufficiency Cohort (CRIC). Am Heart J 2010; 159 (06) 1102-1107
  • 4 Banerjee A, Fauchier L, Vourc'h P. , et al. A prospective study of estimated glomerular filtration rate and outcomes in patients with atrial fibrillation: the Loire Valley Atrial Fibrillation Project. Chest 2014; 145 (06) 1370-1382
  • 5 Proietti M, Lane DA, Lip GYH. Chronic kidney disease, time in therapeutic range and adverse clinical outcomes in anticoagulated patients with non-valvular atrial fibrillation: observations from the SPORTIF Trials. EBioMedicine 2016; 8: 309-316
  • 6 Go AS, Fang MC, Udaltsova N. , et al; ATRIA Study Investigators. Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Circulation 2009; 119 (10) 1363-1369
  • 7 Bansal N, Fan D, Hsu CY, Ordonez JD, Go AS. Incident atrial fibrillation and risk of death in adults with chronic kidney disease. J Am Heart Assoc 2014; 3 (05) e001303
  • 8 Lau YC, Lip GYH. Management of atrial fibrillation in patients with kidney disease. J Atr Fibrillation 2014; 6 (06) 989
  • 9 Lau YC, Proietti M, Guiducci E, Blann AD, Lip GYH. Atrial fibrillation and thromboembolism in patients with chronic kidney disease. J Am Coll Cardiol 2016; 68 (13) 1452-1464
  • 10 Bonde AN, Lip GYH, Kamper A-L. , et al. Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study. J Am Coll Cardiol 2014; 64 (23) 2471-2482
  • 11 Gallagher AM, Setakis E, Plumb JM, Clemens A, van Staa T-P. Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients. Thromb Haemost 2011; 106 (05) 968-977
  • 12 Kirchhof P, Benussi S, Kotecha D. , et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016; 37 (38) 2893-2962
  • 13 Proietti M, Airaksinen KEJ, Rubboli A. , et al; AFCAS Study Group. Synergic impact of oral anticoagulation control and renal function in determining major adverse events in atrial fibrillation patients undergoing percutaneous coronary intervention: insights from the AFCAS registry. Clin Res Cardiol 2017; 106 (06) 420-427
  • 14 Nielsen PB, Lane DA, Rasmussen LH, Lip GYH, Larsen TB. Renal function and non-vitamin K oral anticoagulants in comparison with warfarin on safety and efficacy outcomes in atrial fibrillation patients: a systemic review and meta-regression analysis. Clin Res Cardiol 2015; 104 (05) 418-429
  • 15 Fanola CL, Mooney D, Cowan AJ. , et al. Incidence of severe renal dysfunction among individuals taking warfarin and implications for non-vitamin K oral anticoagulants. Am Heart J 2017; 184: 150-155
  • 16 Bertomeu-González V, Anguita M, Moreno-Arribas J. , et al; FANTASIIA Study Investigators. Quality of anticoagulation with vitamin K antagonists. Clin Cardiol 2015; 38 (06) 357-364
  • 17 Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001; 285 (22) 2864-2870
  • 18 Lip GYH, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010; 137 (02) 263-272
  • 19 Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GYH. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010; 138 (05) 1093-1100
  • 20 Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40 (05) 373-383
  • 21 Schulman S, Kearon C. ; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3 (04) 692-694
  • 22 Olesen JB, Lip GYH, Kamper A-L. , et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med 2012; 367 (07) 625-635
  • 23 Roldán V, Marín F, Manzano-Fernandez S. , et al. Does chronic kidney disease improve the predictive value of the CHADS2 and CHA2DS2-VASc stroke stratification risk scores for atrial fibrillation?. Thromb Haemost 2013; 109 (05) 956-960
  • 24 Friberg L, Benson L, Lip GYH. Balancing stroke and bleeding risks in patients with atrial fibrillation and renal failure: the Swedish Atrial Fibrillation Cohort study. Eur Heart J 2015; 36 (05) 297-306
  • 25 Banerjee A, Fauchier L, Vourc'h P. , et al. Renal impairment and ischemic stroke risk assessment in patients with atrial fibrillation: the Loire Valley Atrial Fibrillation Project. J Am Coll Cardiol 2013; 61 (20) 2079-2087
  • 26 Apostolakis S, Guo Y, Lane DA, Buller H, Lip GYH. Renal function and outcomes in anticoagulated patients with non-valvular atrial fibrillation: the AMADEUS trial. Eur Heart J 2013; 34 (46) 3572-3579
  • 27 Carrero JJ, Evans M, Szummer K. , et al. Warfarin, kidney dysfunction, and outcomes following acute myocardial infarction in patients with atrial fibrillation. JAMA 2014; 311 (09) 919-928
  • 28 Leblond F, Guévin C, Demers C, Pellerin I, Gascon-Barré M, Pichette V. Downregulation of hepatic cytochrome P450 in chronic renal failure. J Am Soc Nephrol 2001; 12 (02) 326-332
  • 29 VanPeer A, Belpaire F, Bogaert M. Warfarin elimination and responsiveness in patients with renal dysfunction. J Clin Pharmacol 1978; 18 (01) 84
  • 30 Van Den Ham HA, Klungel OH, Leufkens HGM, Van Staa TP. The patterns of anticoagulation control and the risk of stroke, bleeding and mortality in patients with non-valvular atrial fibrillation. J Thromb Haemost 2013; 11 (01) 107-115
  • 31 Bonde AN, Lip GYH, Kamper A-L. , et al. Effect of reduced renal function on time in therapeutic range among anticoagulated atrial fibrillation patients. J Am Coll Cardiol 2017; 69 (06) 752-753
  • 32 Brodsky SV, Nadasdy T, Rovin BH. , et al. Warfarin-related nephropathy occurs in patients with and without chronic kidney disease and is associated with an increased mortality rate. Kidney Int 2011; 80 (02) 181-189
  • 33 Chang C-C, Liou H-H, Wu C-L. , et al. Warfarin slows deterioration of renal function in elderly patients with chronic kidney disease and atrial fibrillation. Clin Interv Aging 2013; 8: 523-529
  • 34 Böhm M, Ezekowitz MD, Connolly SJ. , et al. Changes in renal function in patients with atrial fibrillation: an analysis from the RE-LY Trial. J Am Coll Cardiol 2015; 65 (23) 2481-2493
  • 35 Roldán V, Marín F, Fernández H. , et al. Renal impairment in a “real-life” cohort of anticoagulated patients with atrial fibrillation (implications for thromboembolism and bleeding). Am J Cardiol 2013; 111 (08) 1159-1164
  • 36 Lip GYH. Stroke prevention in atrial fibrillation. Eur Heart J 2017; 38 (01) 4-5
  • 37 Lip GYH. Chronic renal disease and stroke in atrial fibrillation: balancing the prevention of thromboembolism and bleeding risk. Europace 2011; 13 (02) 145-148